Journal:

Article Title: A Bipartite Membrane-Binding Signal in the Human Immunodeficiency Virus Type 1 Matrix Protein Is Required for the Proteolytic Processing of Gag Precursors in a Cell Type-Dependent Manner

doi:

Figure Lengend Snippet: Defect in proteolytic processing of HIV-1 Gag precursors in Myr− CD4+ T cells. Myr+ and Myr− CD4+ T-cell lines were generated as described in Materials and Methods. (A and B) Cell lysates from uninfected SupT-1 (lane 1), Myr−/SupT-1 (lane 2), and Myr+/SupT-1 (lane 3) cell lines were prepared by lysing of cells in radioimmunoprecipitation assay (RIPA) lysis buffer. The cell lysates were separated by SDS–12% PAGE and transferred to two nitrocellulose filters and then immunoblotted with an HIV-1-positive human serum (A) or with a monoclonal anti-RTp66/p51 antibody (B). (C) The supernatants from uninfected SupT-1 (lane 1), Myr−/SupT-1 (lane 2), and Myr+/SupT-1 (lane 3) cell lines were harvested after 48 h of incubation with fresh complete medium. The virion-associated proteins from harvested supernatants were concentrated by ultracentrifugation and analyzed by SDS-PAGE and immunoblotting with an HIV-1-positive human serum. (D) Cell lysates from uninfected H9 (lane 1), Myr−/H9 (lane 2), and Myr+/H9 (lane 3) cell lines were prepared by lysing the cells in RIPA lysis buffer. The cell lysates were separate by SDS–12% PAGE and the immunoblotted with an HIV-1-positive human serum.

Article Snippet: The CD4 + T-lymphoid cell line SupT-1 was also obtained from the American Type Culture Collection and was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics.

Techniques: Generated, Radio Immunoprecipitation, Lysis, Incubation, SDS Page, Western Blot

Journal: Frontiers in Immunology

Article Title: Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55 – IL6ST Gene Region in Immature Dendritic Cells

doi: 10.3389/fimmu.2021.816930

Figure Lengend Snippet: Expression of ANKRD55 , IL6ST , and sgp130 isoforms in CD4 + T cells (A, C) and immature moDC (B, D) of MS patients. Panels (A, B) represent the effects of rs7731626 genotype in CD4 + T cells (mean ± SEM; n = 40, Cohort 2; Kruskal–Wallis test) and of rs13186299 genotype in moDC (mean ± SEM; n = 59, Cohorts 1 and 2; Mann–Whitney test), respectively. (C, D) Plot p -values for the three SNPs’ effects on the expression of ANKRD55 , IL6ST , sgp130, sgp130-RAPS, and sgp130-E10 in CD4 + T cells and moDC (Mann–Whitney or Kruskal–Wallis tests). (E , F) represent Pearson correlation of ANKRD55 and IL6ST 2 -Δct values in CD4 + T cells and in moDC of MS patients from panels (A, B) , respectively. ** p ≤ 0.01, **** p ≤ 0.0001. n.s., not significant.

Article Snippet: CD4 + T-helper lymphocytes, CD8 + T cytotoxic lymphocytes, CD19 + B lymphocytes, CD14 + monocytes, and CD56 + natural killer (NK) cells were separated by positive selection using CD4 (Ref. 130-045-101), CD8 (Ref. 130-045-201), CD19 (Ref. 130-050-301), CD14 (Ref. 130-050-201), and CD56 (Ref. 130-050-401) human MicroBeads (all from Miltenyi Biotec) correspondingly, following the manufacturer’s instructions, as described before ( ).

Techniques: Expressing, MANN-WHITNEY

Journal: Journal of the American Society of Nephrology : JASN

Article Title: Moving Biomarkers toward Clinical Implementation in Kidney Transplantation

doi: 10.1681/ASN.2016080858

Figure Lengend Snippet: Selected biomarkers for outcomes in kidney transplantation: summary of current status

Article Snippet: Finally, we offer a framework monitoring strategy for consideration, and we outline likely barriers and potential solutions to clinical adoption of biomarker testing in transplantation. table ft1 table-wrap mode="anchored" t5 caption a7 Authors Assay Name Assay Type Timing Post-Transplant Outcome Discovery Set: Se/sp/ppv/npv Validation Set: Se/sp/ppv/npv Training/Test Sample Biomarker Lifecycle FDA-approved assays Patel and Terasaki 19 CDC crossmatch Microcytotoxicity assay Pretransplant Hyper-AR/early graft loss 0.75/0.97/0.80/0.97 Not applicable, no validation set 225 FDAA: Y; Comm: Y Mahoney et al. 149 Flow crossmatch Flow cytometry Pretransplant Early graft loss (<2 mo) 0.71/0.74/0.33/0.93 Not applicable, no validation set 90 FDAA: Y; Comm: Y Pei et al . 150 Lumine HLA beads; flow cytometry Variable pre-/post-transplant Anti-HLA Ab Details not available in manuscript Not applicable, no validation set 10 FDAA: Y; Comm: Y a Ashokkumar et al . 61 Pleximmune T cytotoxic memory cell assay Rejection episodes Biopsy-proven AR 0.88/0.94/0.93/0.88 1.0/0.86/0.80/1.0 32/11 FDAA: Y; Comm: Y He et al . 63 Cylex-Immuknow Lymphocyte ATP generation assay Serial <30 mo CD4-T cell function Details not available in manuscript Not applicable, no validation set 42 FDAA: Y; Comm: Y Loupy et ald .

Techniques: Transplantation Assay, Biomarker Assay, Flow Cytometry, Cell Function Assay, Binding Assay, Enzyme-linked Immunospot, Enzyme-linked Immunosorbent Assay, Microarray